Asset Details
Do you wish to reserve the book?
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
Do you wish to request the book?
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
2011
Overview
Untreated
de novo
(
n
=421) and secondary (
n
=189) acute myeloid leukemia (AML) patients ⩾60 years received intensified chemotherapy, including daunorubicin 60 mg/m
2
and etoposide 100 mg/m
2
during days 1, 2, 3 with cytarabine 100 mg/m
2
during days 1–7, with a second induction if needed and one consolidation course with these drugs and doses for 2, 2 and 5 days, respectively. In all, 287 (47%) achieved complete remission (CR), 136 (22%) died and 187 (31%) were non-responders. CR rates were 27, 44 and 52% for complex karyotypes, rare aberrations and neither (
P
<0.001), 52 and 37% for
de novo
and secondary AML (
P
=0.003), and 53 and 42% for age 60–69 and ⩾70 years (
P
=0.015). In multivariable analysis, CR predictors included non-complex/non-rare karyotypes (
P
<0.001),
de novo
AML (
P
<0.001), better performance status (PS) (
P
<0.001) and younger age (
P
=0.001). Disease-free (DFS) and overall (OS) survival medians were 6.8 (95% CI: 6.2, 7.8) and 7.2 (95% CI: 6.4, 8.6) months. In multivariable analysis, DFS was shorter for complex karyotypes (
P
<0.001) and increasing white blood count (WBC) (
P
<0.001) and age (
P
=0.038), and OS for complex karyotypes (
P
<0.001), increasing WBC (
P
=0.001) and age (
P
<0.001), poorer PS (
P
<0.001) and secondary AML (
P
=0.010). Outcomes and prognostic factors were similar to those in previous Cancer and Leukemia Group B studies.
Publisher
Springer Science and Business Media LLC,Nature Publishing Group UK,Nature Publishing Group
Subject
/ Age
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Biological and medical sciences
/ Cancer
/ Cytarabine - therapeutic use
/ Daunorubicin - therapeutic use
/ Female
/ Hematologic and hematopoietic diseases
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - mortality
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Male
/ Medicine
/ Oncology
